.Charles Baum, M.D., Ph.D., that supervised Mirati Therapeutics’ $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the controls of young biotech Terremoto Biosciences.Baum’s “substantial knowledge in drug progression, and tried and tested performance history earlier high-impact medicines, are going to contribute,” outbound CEO Peter Thompson, M.D., stated in a July 25 release. Thompson will certainly keep his chair as board chairperson..Baum, a skilled physician-scientist, was the creator, president and CEO of oncology-focused Mirati. Before that, he assisted build cancer cells medications at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will certainly function as CEO at Terremoto, a firm building little particles to target disease-causing proteins– like those discovered in cancerous lump tissues– utilizing covalent connects. Existing treatments that use covalent connects mostly target the amino acid cysteine. Nonetheless, of the twenty amino acids that compose proteins, cysteine is actually the minimum popular.
Terremoto is actually instead targeting some of the crucial amino acids, amino acid lysine, which is actually located in mostly all proteins.Through targeting amino acid lysine and also various other amino acids, Terremoto wishes to alleviate recently undruggable ailments as well as generate first-in-class medications..The biotech, based in South San Francisco, increased $75 million in series A funding in 2022. A little bit of more than a year later on, the biotech much more than doubled that amount in a $175 million collection B.